{"id":"NCT04467697","sponsor":"Marius Pharmaceuticals","briefTitle":"Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men","officialTitle":"A 6 Month, Open Label, Ambulatory Blood Pressure Monitoring (ABPM) Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-18","primaryCompletion":"2020-05-01","completion":"2020-05-01","firstPosted":"2020-07-13","resultsPosted":"2024-06-28","lastUpdate":"2024-06-28"},"enrollment":155,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism, Male"],"interventions":[{"type":"DRUG","name":"SOV2012-F1","otherNames":[]}],"arms":[{"label":"SOV2012-F1-treated","type":"EXPERIMENTAL"}],"summary":"The purpose of this six-month treatment study is\n\n* to assess feasibility of a lower starting dose of SOV2012-F1 (daily dose of 400 mg \\[200 mg with breakfast meal and 200mg with dinner meal\\]) to titrate individual doses to further enhance efficacy and safety.\n* To examine the blood pressure (BP) effects of Marius's oral testosterone undecanoate formulation, SOV2012-F1, using 24-hour ambulatory blood pressure monitoring (ABPM).","primaryOutcome":{"measure":"Change From Baseline in 24-hour Average Ambulatory Systolic Blood Pressure After 120 Days Treatment","timeFrame":"120 days","effectByArm":[{"arm":"SOV2012-F1-treated","deltaMin":128.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["38606384"],"seeAlso":["https://clinicaltrials.gov/ct2/show/NCT03198728"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":155},"commonTop":["Upper Respiratory Tract Infection","Viral upper respiratory tract infection","Hypertension","Influenza","Bronchitis"]}}